Literature DB >> 26541631

Bevacizumab for recurrent primary central nervous system lymphoma: a new treatment?

Karina Nieto1, Leo I Gordon1, Jeffrey Raizer1.   

Abstract

Entities:  

Keywords:  PCNSL; bevacizumab

Mesh：

Substances：

Year:  2015        PMID： 26541631      PMCID： PMC4633937          DOI： 10.1093/neuonc/nov246

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

Review 1.  Recurrent or refractory primary central nervous lymphoma: therapeutic considerations.

Authors:  Saurabh Dahiya; Erin S Murphy; Samuel T Chao; Glen H J Stevens; David M Peereboom; Manmeet S Ahluwalia
Journal:  Expert Rev Anticancer Ther       Date:  2013-09       Impact factor: 4.512

2.  Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.

Authors:  John D Hainsworth; F Anthony Greco; Eric L Raefsky; Dana S Thompson; Scott Lunin; James Reeves; Lynn White; Raven Quinn; Laura M DeBusk; Ian W Flinn
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-28

3.  Primary central nervous system lymphoma.

Authors:  Stephane Doucet; Priya Kumthekar; Jeffrey Raizer
Journal:  Curr Treat Options Oncol       Date:  2013-06

Review 4.  Diagnosis and treatment of primary CNS lymphoma.

Authors:  Agnieszka Korfel; Uwe Schlegel
Journal:  Nat Rev Neurol       Date:  2013-05-14       Impact factor: 42.937

5.  The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma.

Authors:  Brian Patrick O'Neill; Paul A Decker; Christina Tieu; James R Cerhan
Journal:  Am J Hematol       Date:  2013-09-12       Impact factor: 10.047

6.  Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.

Authors:  Patrick G Morris; Denise D Correa; Joachim Yahalom; Jeffrey J Raizer; David Schiff; Barbara Grant; Sean Grimm; Rose K Lai; Anne S Reiner; Kathy Panageas; Sasan Karimi; Richard Curry; Gaurav Shah; Lauren E Abrey; Lisa M DeAngelis; Antonio Omuro
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

7.  R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.

Authors:  John F Seymour; Michael Pfreundschuh; Marek Trnĕný; Laurie H Sehn; John Catalano; Eva Csinady; Nicola Moore; Bertrand Coiffier
Journal:  Haematologica       Date:  2014-06-03       Impact factor: 9.941

8.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Authors:  James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544
  8 in total
  1 in total

1.  Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report.

Authors:  Motomasa Furuse; Naosuke Nonoguchi; Naoki Omura; Mitsuaki Shirahata; Koichi Iwasaki; Toshio Inui; Toshihiko Kuroiwa; Hiroko Kuwabara; Shin-Ichi Miyatake
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-03-23       Impact factor: 1.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.